News
Enhancing Power of Medicare Drug Price, Proposed By Biden
In a recent move, the US President Joe Biden happens to be taking on a bipartisan bogeyman prior to the crucial State of the Union speech, stressing the pharmaceutical industry as well as saying that he will work towards...
Drug Research
CordenPharma Expands Early Clinical Peptide Manufacturing to Launch IND-Targeted Peptide API to Injectable Drug Product Integrated Offer
After an initial expansion of the CordenPharma Frankfurt site for non-GMP manufacturing in 2020, and because of sustained success and exemplary performance delivered by their expert team, CordenPharma is pleased to announce the commissioning of new GMP capacities at...
News
New Treatment For Endometrial Cancer Gets Clearance From NHS
The NHS is all set to come up with groundbreaking immunotherapy that can go on to potentially offer a significant additional time when it comes to women who happen to be battling with advanced endometrial cancer.
As compared to standard...
News
Better Outcomes On Crohns Disease Treatment – UK Research
Top-down treatment by way of infliximab Plus, which is an immunomodulator, goes on to substantially enhance the outcomes for patients with newly diagnosed Crohn’s disease as compared to the accelerated step-up therapy, the UK research has found out.
It is...
News
Cresset Increases Its North America Presence with New Boston Site
Cresset, a provider of integrated in silico solutions for drug discovery has expanded its existing North American presence, with the creation of a new US facility in Boston, one of the world’s leading global hubs for pharma and life...
News
One of Northern Europe’s Largest Production Sites successfully taken over by the Prange Group and Adragos Pharma
The Prange Group and its affiliate Adragos Pharma, one of Europe’s fastest growing CDMOs, has completed the acquisition transaction of Fresenius Kabi production site in Halden, Norway - a leading sterile pharmaceutical manufacturing unit.
This strategic move opens the door...
News
Asahi Kasei offers pharmaceutical excipient Ceolus with nitrite concentration of 0.1 ppm or less
To contribute to reducing the risk of potentially carcinogenic nitrosamine impurities in pharmaceuticals and nutritional supplements, Asahi Kasei now offers Ceolus™ microcrystalline cellulose (MCC) with nitrite levels of 0.1 μg/g (ppm) or less.
In 2018, a potentially carcinogenic nitrosamine impurity...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
Must read